Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)
Lead Sponsor:
Edusa Pharmaceuticals, Inc.
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease (GERD) symptoms in patients who have a history of GERD symptoms and are currently takin...
Eligibility Criteria
Inclusion
- Patients with history of Gastroesophageal Reflux Disease (GERD) symptoms (heartburn, regurgitation, acid taste in mouth).
- Between ages of 18 - 70 inclusive.
- Develop GERD symptoms following ingestion of a refluxogenic meal.
- Able to take a stable Proton Pump Inhibitor (PPI) regimen for duration of study.
- Understand and sign the informed consent form.
Exclusion
- Pregnant or lactating women.
- Allergic to pumosetrag or formulation excipients.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
May 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01161602
End Date
May 1 2011
Last Update
September 21 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States, 85259
2
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
3
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
4
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905